Hefei Hengxin Life Science and Technology Co (301501) Fair Value & Analysis
Consumer Cyclical · CN · Market cap 4.0B CNY
Fair value as of: Jul 9, 2026
From 14 valuation models · updated 32 days ago
Share price +3.2% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥19.30 (bear) to ¥32.16 (bull), base ¥25.73. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 32/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (17 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
17‑month range ¥25.42 – ¥66.37 · fair‑value band ¥19.30 – ¥32.16 · the ¥28.07 price screens above the ¥25.73 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Hefei Hengxin Life Science and Technology Co (301501) currently trades at ¥28.07, while our model-based Fair Value estimate is ¥25.73, implying the stock looks roughly 8.3% fairly valued today. The Quality Score stands at 32/100 (below-average quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Hefei Hengxin Life Science and Technology Co generated revenue of 1.9B CNY at a net margin of 9.3%. Revenue grew 7.5% year over year. It earns a return on equity of 8.5%. Net debt stands at 57.5M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥19.30 (bear case) to ¥32.16 (bull case); at ¥28.07, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 60% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at -22% fair-value upside, at -8%, 301501 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (¥39.39) versus Asset-Based (¥9.54). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hefei Hengxin Life Science and Technology Co., Ltd. engages in the research and development, production, and sale of polylactic acid products in China, North America, Europe, Australia, and internationally.
Full company description
Hefei Hengxin Life Science and Technology Co., Ltd. engages in the research and development, production, and sale of polylactic acid products in China, North America, Europe, Australia, and internationally. It offers paper and clear cups, cup lids, knives, forks, spoons, straws, stirring roads, foaming tableware, food packaging containers, packing bags, cup holders, and cup sleeves. The company was incorporated in 1997 and is based in Hefei, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hefei Hengxin Life Science and Technology Co reported revenue of ¥1.8B in FY2025 versus ¥719M in FY2021, a compound +26.6%/yr. Reported net income was ¥224M in FY2025, compounding +29.2%/yr from FY2021.
Watch 301501: get an alert when its fair value changes →
Peer Group
Packaging & Containers · 273 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaging & Containers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Packaging & Containers stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Stora Enso Oyj STER | kr 101.90 | kr 126.39 | +24% |
| ShenZhen YUTO Packaging Technology Co 002831 | ¥29.10 | ¥20.88 | -28% |
| SCG Packaging Public Company SCGP | 29.00 THB | 16.12 THB | -44% |
| AblePrint Technology Co 7734 | 2,850 TWD | 661.69 TWD | -77% |
| PT Fajar Surya Wisesa Tbk, FASW | 5,312 IDR | 1,194 IDR | -78% |
| Taiwan Hon Chuan Enterprise Co 9939 | 132.50 TWD | 127.06 TWD | -4% |
| Time Technoplast Limited TIMETECHNO | ₹206.82 | ₹161.42 | -22% |
| EPL Limited 500135 | ₹222.25 | ₹111.65 | -50% |
| Ton Yi Industrial Corp 9907 | 15.15 TWD | 23.17 TWD | +53% |
| Dongwon Systems Corporation 014820 | 19,330 KRW | 31,473 KRW | +63% |
Compare Hefei Hengxin Life Science and Technology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Hefei Hengxin Life Science and Technology Co (301501) overvalued or undervalued?
What is the fair value of 301501?
What is the quality score of 301501?
What is the revenue of Hefei Hengxin Life Science and Technology Co (301501)?
What is the net profit margin of 301501?
Does Hefei Hengxin Life Science and Technology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hefei Hengxin Life Science and Technology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.